Table S5. Characteristics of participants with 50% reduction in blasts in bone marrow and best response to pimasertib treatment ≥ Patient Regimen Dose, Disease Cytogenetics Mutational Maximum % reduction Best Time to Duration of best mg, status from baseline in bone overall response response (days) BID marrow blast response (days) 1 1 23 MPD Unknown JAK2 SD 29 46 –90.0 2 1 23 MDS Unknown K-Ras NK –72.7 3 1 30 AML Unfavourable WT SD 29 50 –58.3 4 1 30 MDS Unknown WT PR 29 175 –83.3 5 1 42 AML Intermediate WT SD 30 1 –73.8 6 2 8 AML Unfavourable WT SD 26 28 –65.9 7 2 60 MPD Unknown K-Ras SD 29 28 –50.0 8 2 75 AML Unfavourable WT SD 29 28 –71.4 9 2 75 AML Favourable FLT3 SD 29 27 –91.2
Table S5. Characteristics of participants with ≥ 50% reduction in blasts in bone marrow and best response to pimasertib treatment Patient Regimen Dose, mg, BID Disease Cytogenetics Mutational status Maximum % reduction from baseline in bone marrow blast Best overall response Time to response (days) Duration of best response (days) 1 1 23 MPD Unknown JAK2 –90.0 SD 29 46 2 1 23 MDS Unknown K-Ras –72.7 NK 3 1 30 AML Unfavourable WT –58.3 SD 29 50 4 1 30 MDS Unknown WT –83.3 PR 29 175 5 1 42 AML Intermediate WT –73.8 SD 30 1 6 2 8 AML Unfavourable WT –65.9 SD 26 28 7 2 60 MPD Unknown K-Ras –50.0 SD 29 28 8 2 75 AML Unfavourable WT –71.4 SD 29 28 9 2 75 AML Favourable FLT3 –91.2 SD 29 27
bcj2015103x1.docx